GD2 CAR T cells

BIOLOGICAL3 trials

Sponsors

Stanford University, University College, London

Conditions

Diffuse Midline Glioma, H3 K27M-MutantGlioma of BrainstemGlioma of Spinal CordNeuroblastoma

Phase 1

GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)

RecruitingNCT04196413

Stanford UniversityGlioma of Brainstem, Glioma of Spinal Cord

Start: 2020-06-04End: 2043-07-31Target: 97Updated: 2026-01-26

CAR T Cells to Target GD2 for DMG

RecruitingNCT05544526

University College, LondonDiffuse Midline Glioma, H3 K27M-Mutant

Start: 2023-08-15End: 2042-08-01Target: 12Updated: 2026-08-11

Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma

Active, not recruitingNCT05990751

University College, LondonNeuroblastoma

Start: 2024-04-19End: 2041-12-01Target: 12Updated: 2026-04-24

Related Papers

Abstract 6463: Longitudinal single-cell atlas of GD2-CAR T cell therapy in H3K27M-mutant diffuse midline glioma identifies humoral and cellular anti-CAR immunity

Cancer Research2026-04-03

CTIM-05. HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA

Neuro-Oncology2025-11-01

Abstract 7123: Unravelling temporal dynamics of GD2-CAR T cell therapy in H3K27M-mutant diffuse midline glioma through comprehensive single-cell and multi-omic profiling

Cancer Research2025-04-21

Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomas.

2024-11-1379 citations

IMMU-60. MYELOID POPULATIONS MODULATE GD2 CAR T CELL ACTIVITY IN DIFFUSE MIDLINE GLIOMA

Neuro-Oncology2024-11-01

DIPG-47. SEQUENTIAL INTRAVENOUS AND INTRACEREBROVENTRICULAR GD2-CAR T-CELL THERAPY FOR H3K27M-MUTATED DIFFUSE MIDLINE GLIOMAS

Neuro-Oncology2024-06-18

Research Findings of GD2 CAR T-Cell Therapy for Diffuse Midline Gliomas

Oncology Times2023-07-05

Abstract 959: Immune signatures of GD2 CAR T cell activity in H3K27M+ diffuse midline glioma patients

Cancer Research2023-04-043 citations

Abstract CT001: Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T cells

Cancer Research2022-06-157 citations

DIPG-15. Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T-cells

Neuro-Oncology2022-06-012 citations

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.

2022-02-07596 citations

EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG

Neuro-Oncology2021-06-016 citations

OMIC-11. SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+ DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY

Neuro-Oncology2021-06-013 citations